ID   253J-BV
AC   CVCL_7937
SY   253JB-V; 253J B-V; 253JBV; 253J-Bladder-V
DR   BTO; BTO:0004894
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN10987963
DR   CCLE; 253JBV_URINARY_TRACT
DR   Cell_Model_Passport; SIDM01624
DR   Cosmic; 846282
DR   Cosmic; 1082645
DR   Cosmic; 1938695
DR   DepMap; ACH-000026
DR   GEO; GSM136239
DR   IARC_TP53; 30015
DR   KCLB; 80002
DR   LiGeA; CCLE_144
DR   PharmacoDB; 253JBV_15_2019
DR   Wikidata; Q54583655
RX   PubMed=7658585;
RX   PubMed=29732388;
RX   PubMed=31068700;
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Characteristics: Metastatic phenotype. Obtained after 5 serial passages of the parent cell line in the bladder of nude mice.
CC   Doubling time: 49 +- 5 hours (PubMed=7658585).
CC   Microsatellite instability: Stable (MSS) (PubMed=31068700).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Lymph node.
ST   Source(s): KCLB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9
ST   D3S1358: 15
ST   D5S818: 10,12
ST   D7S820: 9
ST   FGA: 23,24
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_7935 ! 253J
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 18
//
RX   PubMed=7658585; DOI=10.1016/S0022-5347(01)66923-4;
RA   Dinney C.P.N., Fishbeck R., Singh R.K., Eve B., Pathak S., Brown N.,
RA   Xie B., Fan D., Bucana C.D., Fidler I.J., Killion J.J.;
RT   "Isolation and characterization of metastatic variants from human
RT   transitional cell carcinoma passaged by orthotopic implantation in
RT   athymic nude mice.";
RL   J. Urol. 154:1532-1538(1995).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//